196 related articles for article (PubMed ID: 21288186)
21. Telomeres rather than telomerase a key target for anti-cancer therapy?
Boukamp P; Mirancea N
Exp Dermatol; 2007 Jan; 16(1):71-9. PubMed ID: 17181645
[TBL] [Abstract][Full Text] [Related]
22. Telomere inhibition and telomere disruption as processes for drug targeting.
Rezler EM; Bearss DJ; Hurley LH
Annu Rev Pharmacol Toxicol; 2003; 43():359-79. PubMed ID: 12540745
[TBL] [Abstract][Full Text] [Related]
23. Telomere maintenance mechanisms as a target for drug development.
Bearss DJ; Hurley LH; Von Hoff DD
Oncogene; 2000 Dec; 19(56):6632-41. PubMed ID: 11426649
[TBL] [Abstract][Full Text] [Related]
24. Telomere dysfunction and telomerase activation in cancer--a pathological paradox?
Calcagnile O; Gisselsson D
Cytogenet Genome Res; 2007; 118(2-4):270-6. PubMed ID: 18000380
[TBL] [Abstract][Full Text] [Related]
25. Crossroads of telomere biology and anticancer drug discovery.
Seimiya H
Cancer Sci; 2020 Sep; 111(9):3089-3099. PubMed ID: 32579791
[TBL] [Abstract][Full Text] [Related]
26. Ageing and cancer: the telomere and telomerase connection.
Shay JW; Wright WE
Novartis Found Symp; 2001; 235():116-25; discussion 125-9, 146-9. PubMed ID: 11280022
[TBL] [Abstract][Full Text] [Related]
27. Association of a Platinum Complex to a G-Quadruplex Ligand Enhances Telomere Disruption.
Charif R; Granotier-Beckers C; Bertrand HC; Poupon J; Ségal-Bendirdjian E; Teulade-Fichou MP; Boussin FD; Bombard S
Chem Res Toxicol; 2017 Aug; 30(8):1629-1640. PubMed ID: 28657713
[TBL] [Abstract][Full Text] [Related]
28. Treating Cancer by Targeting Telomeres and Telomerase.
Ivancich M; Schrank Z; Wojdyla L; Leviskas B; Kuckovic A; Sanjali A; Puri N
Antioxidants (Basel); 2017 Feb; 6(1):. PubMed ID: 28218725
[TBL] [Abstract][Full Text] [Related]
29. Combined treatment with emodin and a telomerase inhibitor induces significant telomere damage/dysfunction and cell death.
Liu R; Liu J; Wang S; Wang Y; Zhang T; Liu Y; Geng X; Wang F
Cell Death Dis; 2019 Jul; 10(7):527. PubMed ID: 31296842
[TBL] [Abstract][Full Text] [Related]
30. Targeting telomerase and telomeres: a click chemistry approach towards highly selective G-quadruplex ligands.
Moorhouse AD; Haider S; Gunaratnam M; Munnur D; Neidle S; Moses JE
Mol Biosyst; 2008 Jun; 4(6):629-42. PubMed ID: 18493662
[TBL] [Abstract][Full Text] [Related]
31. Reduced or diminished stabilization of the telomere G-quadruplex and inhibition of telomerase by small chemical ligands under molecular crowding condition.
Chen Z; Zheng KW; Hao YH; Tan Z
J Am Chem Soc; 2009 Aug; 131(30):10430-8. PubMed ID: 19588966
[TBL] [Abstract][Full Text] [Related]
32. Alternative lengthening of telomeres in mammalian cells.
Henson JD; Neumann AA; Yeager TR; Reddel RR
Oncogene; 2002 Jan; 21(4):598-610. PubMed ID: 11850785
[TBL] [Abstract][Full Text] [Related]
33. Targeting ALT: the role of alternative lengthening of telomeres in pathogenesis and prevention of cancer.
Bollmann FM
Cancer Treat Rev; 2007 Dec; 33(8):704-9. PubMed ID: 17933469
[TBL] [Abstract][Full Text] [Related]
34. G-quadruplexes as therapeutic targets.
Neidle S; Read MA
Biopolymers; 2000-2001; 56(3):195-208. PubMed ID: 11745111
[TBL] [Abstract][Full Text] [Related]
35. Telomere lengthening in telomerase-negative cells: the ends are coming together.
Scheel C; Poremba C
Virchows Arch; 2002 Jun; 440(6):573-82. PubMed ID: 12070595
[TBL] [Abstract][Full Text] [Related]
36. Platinum(II) phenanthroimidazoles for targeting telomeric G-quadruplexes.
Castor KJ; Mancini J; Fakhoury J; Weill N; Kieltyka R; Englebienne P; Avakyan N; Mittermaier A; Autexier C; Moitessier N; Sleiman HF
ChemMedChem; 2012 Jan; 7(1):85-94. PubMed ID: 22052801
[TBL] [Abstract][Full Text] [Related]
37. Anticancer therapy targeting telomeres and telomerase : current status.
Parkinson EK; Minty F
BioDrugs; 2007; 21(6):375-85. PubMed ID: 18020621
[TBL] [Abstract][Full Text] [Related]
38. PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy.
Salvati E; Scarsella M; Porru M; Rizzo A; Iachettini S; Tentori L; Graziani G; D'Incalci M; Stevens MF; Orlandi A; Passeri D; Gilson E; Zupi G; Leonetti C; Biroccio A
Oncogene; 2010 Nov; 29(47):6280-93. PubMed ID: 20802516
[TBL] [Abstract][Full Text] [Related]
39. An evaluation cascade for G-quadruplex telomere targeting agents in human cancer cells.
Gunaratnam M; Neidle S
Methods Mol Biol; 2010; 613():303-13. PubMed ID: 19997892
[TBL] [Abstract][Full Text] [Related]
40. Rational design of acridine-based ligands with selectivity for human telomeric quadruplexes.
Sparapani S; Haider SM; Doria F; Gunaratnam M; Neidle S
J Am Chem Soc; 2010 Sep; 132(35):12263-72. PubMed ID: 20718414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
